Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Aquestive Therapeutics ( (AQST) ) is now available.
On March 30, 2026, Aquestive Therapeutics reported that it had received preliminary comments and successfully completed an in-person Type A meeting with the U.S. Food and Drug Administration regarding the planned resubmission of its New Drug Application for Anaphylm, a sublingual epinephrine prodrug film for Type 1 allergic reactions including anaphylaxis. The FDA provided clarifying feedback on pharmacokinetic and human factors study designs, acknowledged packaging modifications to improve usability, and aligned with the company on key study elements, enabling Aquestive to reaffirm its intention to resubmit the Anaphylm application in the third quarter of 2026 while it also advances parallel regulatory efforts in Canada and the European Union, a step that could strengthen its position in the emerging market for non-invasive epinephrine rescue treatments if the product is ultimately approved.
The most recent analyst rating on (AQST) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
The score is primarily held down by weak financial performance—negative gross profit, widening losses, negative equity, and persistent cash burn. Offsetting factors include a more defined regulatory/commercial roadmap and financing support discussed on the earnings call, while technicals and valuation provide only neutral-to-limited support.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a U.S.-based pharmaceutical company that develops and manufactures medicines using proprietary oral film and other delivery technologies, operating both its own proprietary product business and as a contract development and manufacturing organization for licensees. Headquartered in New Jersey with manufacturing in Indiana, it is a leading producer of oral film medications such as those using its PharmFilm technology, and is advancing its AdrenaVerse epinephrine prodrug platform targeting severe allergic reactions and dermatological conditions, including the Anaphylm sublingual film and AQST-108 topical gel.
Average Trading Volume: 4,794,135
Technical Sentiment Signal: Sell
Current Market Cap: $490.6M
For an in-depth examination of AQST stock, go to TipRanks’ Overview page.